Oncology · Clinical trials
Neuroendocrine Tumours Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About neuroendocrine tumours — and why its trials are hard
Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms arising from hormone-producing cells, most often in the gastrointestinal tract (including midgut carcinoids) and pancreas, ranging from indolent well-differentiated tumors to aggressive high-grade carcinomas. Many are functional, secreting hormones that cause syndromes such as carcinoid syndrome. Treatment is notably multimodal and biomarker-driven by somatostatin receptor expression. Somatostatin analogues (octreotide LAR, validated for antiproliferative effect in PROMID; lanreotide in CLARINET) are foundational, controlling both symptoms and tumor growth. For progressive disease, molecularly targeted agents everolimus (mTOR inhibitor; RADIANT-3 in pancreatic NET, RADIANT-4 in GI/lung NET) and sunitinib (VEGFR inhibitor; pancreatic NET) extend progression-free survival. Peptide receptor radionuclide therapy with lutetium Lu-177 dotatate (NETTER-1) delivers targeted radiation to somatostatin-receptor-positive tumors with a striking PFS benefit. Telotristat ethyl controls refractory carcinoid syndrome diarrhea. Compared with many rare cancers, NETs enjoy a relatively rich, well-validated therapeutic armamentarium, though sequencing remains individualized and high-grade neuroendocrine carcinomas have far worse outcomes and fewer options.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Lanreotide (Somatuline Depot) | 2014 | Unresectable, well/moderately differentiated, locally advanced/metastatic GEP-NETs (antiproliferative) | CLARINET (phase 3) | Progression-free survival | Marked PFS prolongation, HR 0.47 vs placebo |
| Octreotide LAR (Sandostatin LAR) | 1998 | Symptom control in carcinoid syndrome; antiproliferative benefit in midgut NETs | PROMID (phase 3, antiproliferative evidence) | Time to tumor progression | Median TTP 14.3 vs 6.0 mo vs placebo in midgut NETs |
| Everolimus (Afinitor) | 2011 | Progressive advanced pancreatic NET (2011); expanded to GI and lung NET (2016) | RADIANT-3 (panNET); RADIANT-4 (GI/lung NET) | Progression-free survival | panNET median PFS 11.0 vs 4.6 mo; RADIANT-4 median PFS 11.0 vs 3.9 mo, HR 0.48 |
| Sunitinib (Sutent) | 2011 | Progressive, well-differentiated advanced pancreatic NET | A6181111 (phase 3) | Progression-free survival | Median PFS 11.4 vs 5.5 mo, HR 0.42 |
| Lutetium Lu-177 dotatate (Lutathera) | 2018 | Somatostatin-receptor-positive GEP-NETs (peptide receptor radionuclide therapy) | NETTER-1 (phase 3) | Progression-free survival | PFS markedly prolonged, HR 0.21 vs high-dose octreotide |
| Telotristat ethyl (Xermelo) | 2017 | Carcinoid syndrome diarrhea inadequately controlled by somatostatin analogue therapy | TELESTAR (phase 3) | Reduction in bowel movement frequency | Significant reduction in daily bowel movements vs placebo |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in neuroendocrine tumours development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Bevacizumab — SWOG S0518 (phase 3, bevacizumab vs interferon added to octreotide) | Did not improve progression-free survival over interferon alfa-2b | Anti-VEGF benefit not superior to comparator; endpoint not met in carcinoid NETs |
| Interferon alfa — Historical randomized comparisons | Largely supplanted; modest efficacy with substantial toxicity | Poor tolerability and limited incremental benefit versus somatostatin analogues |
Choosing the right endpoint
Primary endpoints that matter in neuroendocrine tumours trials
- Progression-free survival (PFS) — Dominant primary endpoint across targeted, somatostatin-analogue, and PRRT trials in indolent NETs
- Time to tumor progression (TTP) — Primary endpoint demonstrating octreotide's antiproliferative effect in PROMID
- Overall survival (OS) — Long follow-up needed given indolent biology; often a secondary or confirmatory endpoint
- Somatostatin receptor expression — Predictive biomarker (via Ga-68 DOTATATE imaging) selecting patients for analogues and Lu-177 PRRT
- Symptom/biomarker control — Bowel movement frequency and hormone/5-HIAA levels are key functional endpoints in carcinoid syndrome
How iNGENū runs neuroendocrine tumours trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Neuroendocrine Tumours clinical trials — FAQs
Are somatostatin analogues only for symptom control?
What is Lu-177 dotatate (Lutathera)?
How is treatment sequenced in advanced NETs?
Ready to discuss your neuroendocrine tumours trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal